Table 5.

Patients in the boost group experienced transient storage symptoms at 24 and 36 months after BT, whereas those in the monotherapy group did not (P < 0.05). The storage symptom score of patients in the boost group significantly increased at 3 months after BT, and had a transient worsening at 24 and 36 months, compared with the monotherapy group (P < 0.05). The voiding symptom score of patients in the boost group had a transient worsening only at 36 months compared with the monotherapy group (P < 0.05). With the OABSS and IPSS-QOL scores, patients treated with EBRT experienced transient storage symptoms at 24 and 36 months after BT, whereas those who did not undergo EBRT did not.

SD = standard deviation, IPSS = International Prostate Symptom Score, OABSS = Overactive Bladder Symptom Score.

Baseline versus ^†p < 0.05, ^‡p < 0.01. Between-group difference *p < 0.05, **p < 0.01.